Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, David R. Gandara, Fabrice Barlési et al.|The Lancet|2016Cited by 4.8k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Yi‐Long Wu et al.|The Lancet|2019Cited by 3.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Fátima Cardoso, Eric P. Winer, Martine Piccart et al.|Annals of Oncology|2016Cited by 2.1k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortés, Gallardo Carlos, David W. Cescon et al.|The Lancet|2020Cited by 1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAlessandra Gennari, Nadia Harbeck, Fabrice André et al.|Annals of Oncology|2021Cited by 1.4k